Study of Efficacy and Safety of Investigational Treatments in Patients With

Moderate to Severe Hidradenitis Suppurativa

Estimated Study Completion Date May 10, 2021

 

ID number: NCT03827798

Sponsor: Novartis Pharmaceuticals

Brief Summary:

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533 and LYS006 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533 and LYS006 have an adequate clinical profile for further clinical development.

 

https://clinicaltrials.gov/ct2/show/NCT03827798?recrs=a&cond=Hidradenitis+Suppurativa&cntry=US&draw=2&rank=13

 

Contact: 

Novartis Pharmaceuticals

1-888-669-6682 or +41613241111

novartis.email@novartis.com

 

Locations:

 

United States, Florida

Novartis Investigative Site

Tampa, Florida, United States, 33609

 

United States, Georgia

Novartis Investigative Site

Sandy Springs, Georgia, United States, 30328

 

United States, Massachusetts

Novartis Investigative Site

Boston, Massachusetts, United States, 02215

 

United States, Nebraska

Novartis Investigative Site

Omaha, Nebraska, United States, 68144

 

Hungary

Novartis Investigative Sites

Debrecen, Hungary, 4032

Novartis Investigative Site

 

Pecs, Hungary, 7632

Novartis Investigative Site

 

Szeged, Hungary, H-6725

Get Updates

Affiliated With

  • Instagram
  • Twitter
  • Facebook Social Icon
  • Pinterest

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  Hidradenitis Suppurativa Online

PO Box 73244 Puyallup, WA 98373  |  253.256.1579